Current available evidence supports specific therapeutic fragility for each SCLC subtype49, ranging from the potential efficacy of SCLC-A against B-cell lymphoma 2 (BCL-2) inhibitors and agents of DLL3, to the benefit of SCLC-N towards aurora kinase inhibitors and SCLC-P to PARP inhibitors, antimetabolite agents, and/or laser kinase inhibitors53-55. Here, BCL2 is linked to small cell lung carcinoma.